Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amylyx Pharmaceuticals
Fierce Biotech
Amylyx discontinues rare neuro program after missing ph. 2 mark
The phase 2 portion of the trial found no difference in patients receiving AMX0035 compared to placebo at 24 weeks.
Gabrielle Masson
Aug 27, 2025 10:40am
Amylyx names exec to lead GLP-1 receptor antagonist launch
Jan 6, 2025 10:40am
A revival in neuro therapeutics
Oct 11, 2024 8:37am
Amylyx to pull failed ALS drug from market, cut 70% of staff
Apr 4, 2024 10:06am
Amylyx's ALS drug Albrioza rebuffed by EU regulator—again
Oct 13, 2023 11:24am
Amylyx's ALS drug Relyvrio continues to shine
Aug 11, 2023 11:32am
